The integration of photothermal therapy (PTT) with chemotherapy and immunotherapy holds great promise for improving cancer treatment efficacy, yet achieving precise control over drug release and synergistic modulation of the immunosuppressive tumor microenvironment (TME) remains challenging. Herein, we report a hollow CuS-based nanoplatform that synergistically combines NIR-triggered photothermal-chemotherapy with PD-L1 suppression for enhanced antitumor immunity. The hollow CuS nanoparticles exhibit exceptional photothermal conversion efficiency under 980 nm irradiation, while the phase-change material (PCM) of lauric acid enables controlled release of curcumin (Cur) in response to localized hyperthermia. In vitro studies demonstrate that the released Cur synergistically enhances photothermal ablation, inducing immunogenic cell death (ICD) via ROS generation, mitochondrial dysfunction, and damage-associated molecular patterns (DAMPs) release. Notably, Cur downregulates PD-L1 expression in tumor cells by inhibiting the EGFR-STAT3 signaling axis, thereby alleviating immune evasion. In vivo, the nanoplatform (CuS@PCM@Cur) shows NIR-triggered temperature elevation, achieving potent tumor growth suppression. When combined with anti-PD-1 therapy, CuS@PCM@Cur after laser irradiation further amplifies antitumor immunity by increasing cytotoxic T lymphocyte infiltration and dendritic cell maturation while reducing regulatory T cells in the TME. Comprehensive biosafety evaluations confirm minimal systemic toxicity. This work presents a rationally designed nanotherapeutic strategy that synchronizes physical ablation, chemotherapy, and immune reprogramming, offering a promising multimodal approach to combat resistant malignancies.